ERBB2 and gastric cancer: Additionally, it exerts inhibitory effects on tumors with low HER2 expression and trastuzumab-resistant cell lines (52).In a study involving patients with previously treated advanced HER2-positive gastric cancer, the ORR in the HER2 high-expression cohort was 56%, with a remission duration of 9.7 months.